Table 7.
The effect of several drugs on IMV and EEV entrya
| Drug concentration | Target | IMV (%) | EEV (%) |
|---|---|---|---|
| Pertussis toxin (500 ng/ml) | Trimeric G | 100b | 100b |
| Cholera toxin (500 ng/ml) | Trimeric G | 100 | 100 |
| Alf4− | Trimeric G | 100 | 100 |
| Wortmannin (0.5 μM) | PI3 kinase | 100 | 100 |
| PMA (100 nM) | PKC | 50 | 100 |
| Staurosporin (200 nM) | PK | 39 | 100 |
| Calphostin C (250 nM) | PKC | 30 | 100 |
| BIS (10 μM) | PKC | 60 | 100 |
| Genistein (25 μM) | PTK | 65 | 100 |
| Genistein (200 μM) | PTK | 31 | 77 |
| Tyrphostin 23 (25 μM) | PTK | 57 | 100 |
| Tyrphostin 23 (100 μM) | PTK | 28 | 80 |
| Myr. A (500 nM) | PKA | 100 | 100 |
| U73122 (20 μM) | PLC | 100 | 100 |
a
Target, the intracellular target of the drug; Trimeric G, trimeric G proteins; PKC, protein kinase C; PK, protein kinase; PTK, protein tyrosine kinase; PKA, protein kinase A; PLC, phospholipase C; Alf4−, aluminium fluoride; PMA, phorbol 12-myristate 13-acetate; BIS, Bisindolylmaleimide; Myr. A, myristoylated peptide mimicking the active site of protein kinase A.
b
In each case, 30 treated cells were counted and the amount is expressed as a percentage of the control, which consisted of untreated cells.